iSpecimen Inc Cash Flow Conversion Efficiency
iSpecimen Inc cash flow conversion efficiency. Based on the latest financial reports, iSpecimen Inc (ISPC) has a cash flow conversion efficiency ratio of -0.397x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-689.62K) by net assets ($1.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of iSpecimen Inc (2018–2025)
Cash flow conversion efficiency of iSpecimen Inc from 2018 to 2025. This chart illustrates how iSpecimen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ISPC stock price and chart for real-time trading data and today's change.
iSpecimen Inc Cash Flow Conversion Ratio Explained
iSpecimen Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
iSpecimen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of iSpecimen Inc ranked by their cash flow conversion efficiency. Also see iSpecimen Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HYDRIX Ltd
AU:HYD
|
0.279x |
|
Unicorn AIM VCT plc
LSE:UAV
|
-0.006x |
|
Aker Carbon Capture ASA
OL:ACC
|
-0.772x |
|
ELEMENT NUTR.SCIENCES
F:93X
|
0.014x |
|
Foresight Enterprise VCT PLC
LSE:FTF
|
-0.001x |
|
Metalex Ventures Ltd.
V:MTX
|
-0.095x |
|
Pensana Rare Earths Plc
LSE:PRE
|
-0.065x |
|
Entreparticuli
PA:ALENT
|
-4.815x |
Annual Cash Flow Conversion Efficiency for iSpecimen Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of iSpecimen Inc from 2018 to 2025. Review free cash flow generation of iSpecimen Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.09 Million | $-4.24 Million | -1.373x | +44.98% |
| 2024-12-31 | $3.31 Million | $-8.26 Million | -2.496x | -318.63% |
| 2023-12-31 | $9.74 Million | $-5.81 Million | -0.596x | -108.13% |
| 2022-12-31 | $20.31 Million | $-5.82 Million | -0.286x | +20.01% |
| 2021-12-31 | $29.79 Million | $-10.67 Million | -0.358x | -3487.29% |
| 2020-12-31 | $-27.28 Million | $-288.38K | 0.011x | -91.04% |
| 2019-12-31 | $-22.72 Million | $-2.68 Million | 0.118x | -18.96% |
| 2018-12-31 | $-18.42 Million | $-2.68 Million | 0.146x | -- |
About iSpecimen Inc
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have ac… Read more